Alzheimer Europe

Making dementia a priority:
changing perceptions, practice and policy.

CLINICAL TRIALS WATCH

ACCESSIBLE EASY READ INFORMATION ON:

GSK4527226 STUDY

Alzheimer Europe • R.C.S. LUXEMBOURG F2773 • 5 Heienhaff, L-1736 Senningerberg
Tel. +352 29 79 70 • Fax +352 29 79 72 • info@alzheimer-europe.org • www.alzheimer-europe.org

GSK4527226 study

1. Study Information	
Name of the study	Open-label extension study in participants with early Alzheimer's disease
Study sponsor	GlaxoSmithKline
Disease	Early Alzheimer's disease
Phase	Phase II - Open Label Extension study

2. Information about the drug that will be tested in the study	
Name of drug	GSK4527226
Administration	The drug will be administered via an intravenous infusion (an injection into the vein).
Is the drug already on the market for another medical condition?	No
Will all participants receive the same drug?	All participants will receive GSK4527226.

3. Information about participating in the trial	
What are the researchers trying to find out?	• The purpose of the study is to evaluate the long-term safety and efficacy of GSK4527226 in people with early Alzheimer's disease (including mild cognitive impairment and mild dementia due to Alzheimer's disease) who have completed the PROGRESS-AD study.
How long will the treatment last?	• Around 2 years.
What your involvement will entail?	• During the study, participants will be asked to complete tests that will assess their cognition, function, memory and activities of daily living (i.e. CDR-SB, iADRS, ADAS-Cog14, ADCS-iADL, ADCOMS) • Participants will undergo brain scans (MRI) • Complete some laboratory tests to evaluate the emergent adverse events (unfavourable signs, symptoms or diseases

	temporally associated with the use of the drug tested in the study). Further information on the procedures, tests and number of visits can be obtained from the study team.

4. Who can participate in this study?	
Who can participate in the study?	To take part in the study, participants must: • Be between 50 and 85 years old • Have completed the parent study named PROGRESS-AD • Have a study partner who has a sufficient contact with the participant, is willing to participate in study procedures throughout the study duration and report on cognitive and functional abilities • For female participants: not be pregnant or breastfeeding • Use contraception.
Who cannot participate in the study?	Exclusion criteria include: • Evidence of any Amyloid related imaging abnormalities (ARIA) or cerebral macrohemorrhage • A disease or condition that may interfere with the safety, tolerability and/or study assessments • Newly identified conditions or diseases such as infection(s) that may affect the central nervous system, diagnosed cancer, genetic predisposition for clotting disorder or hemorrhagic disease • Severe alcohol and/or substance use disorder.

	The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.

5. Where and when will the study be conducted?	
European countries involved in the trial (active)	• Finland • France • Germany • Norway • Spain • Sweden • UK
European countries that will be involved in the trial (planned)	• Italy • Netherlands
Estimated start date of recruitment	November 2025

6. Information for your doctor			
Clinicaltrials.gov identifier	NCT07105709	**EU CT Number**	2025-521107-42-00
Study contact information	GSKClinicalSupportHD@gsk.com		
Link to full text	https://clinicaltrials.gov/study/NCT07105709 https://euclinicaltrials.eu/ctis-public/view/2025-521107-42-00		

✓ The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov, CTIS websites) in April 2026.

✓ This document has been reviewed by a member of the European Dementia Carers Working Group.